Bill Rich

Portal Instruments Welcomes William (Bill) Rich to the Board of Directors


June 7th, 2023 Cambridge, MA – Portal Instruments is pleased to announce that Bill Rich has joined its Board of Directors. Mr. Rich is a seasoned executive with vast leadership experience in biotechnology, medical devices, and pharmaceuticals.


With extensive experience in building and leading high-performing organizations, Mr. Rich brings a wealth of knowledge to the company. Currently, he serves as the president of Rich and Associates consulting, leading highly complex and global projects over a broad spectrum of technical, strategic, and organizational initiatives in operations, research, and development.


Before joining the Portal Instruments board, Mr. Rich served as an Advisory Board Member at PBS Biotech, where he engaged the CEO and C-level staff on organizational and governance systems design as well as corporate financing. He also served as an Advisory Board Member at Stevanato Group, where he led executive team members in creating new capabilities and industrialization of existing capabilities in conjunction with business development and acquisitions activities.


For almost 30 years, Mr. Rich worked at Amgen, where he retired as the Vice President of Device Technologies. At Amgen, he was responsible for Final Products Technologies, which included primary container science and engineering, packaging and labeling, human factors, device engineering, and advanced device technologies. During his time at Amgen, Mr. Rich launched ten new combination products, including two wearable drug infusion devices, one reusable autoinjector, and seven single-use autoinjectors.

In addition to his consultancy work, Mr. Rich serves as the Chair of the Student Mentoring and Engagement Committee for the Corporate Relations Board at Keck Graduate Institute, advising and supporting initiatives that prepare KGI students for productive careers in the life sciences industry.


“We are thrilled to welcome Bill Rich to our Board of Directors,” said Patrick Anquetil, CEO of Portal Instruments. “His extensive leadership experience in the biotechnology and pharmaceutical industry, coupled with his proven track record in supply chain, operations, and R&D, will be invaluable to our company as we continue to innovate and work towards bringing our needle-free drug delivery system to market.”


Mr. Rich holds a Bachelor of Science degree in Marine Ecology from McGill University and a Master of Science degree in Biostatistics from the University of Southern California.


About Portal Instruments

Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high-viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real-time tracking and reporting set a new standard for monitoring adherence and potentially improving patient outcomes. Portal Instruments is ISO 13485:2016 certified. For more information, please visit or follow @portalcambridge on Twitter.



Patrick Anquetil